ScholarIQanswers from OpenAlex & ORCID
Anil Kapoor
ResearcherPublications, citations & collaboration network
Anil Kapoor is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Anil Kapoor have?
ScholarIQindexed works
Anil Kapoor has 635 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Anil Kapoor have?
ScholarIQcitation count
Anil Kapoor has 16,332 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Anil Kapoor?
ScholarIQh-index
Anil Kapoor has an h-index of 55 in OpenAlex.
What is the i10-index of Anil Kapoor?
ScholarIQi10-index
Anil Kapoor has an i10-index of 254 in OpenAlex.
What is the ORCID of Anil Kapoor?
ScholarIQorcid
The ORCID for Anil Kapoor is on the source record.
What is the OpenAlex record for Anil Kapoor?
ScholarIQopenalex
The OpenAlex for Anil Kapoor is on the source record.
What are the most-cited papers on Anil Kapoor?
ScholarIQmost cited works
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
Gary R. Hudes, Michael A. Carducci, Piotr Tomczak, Janice Dutcher, Robert A. Figlin, Anil Kapoor, Elżbieta Starosławska, Jeffrey A. Sosman, David McDermott, I. Bodrogi, Zoran Kovačević, Vladimir Lesovoy, Ingo G.H. Schmidt‐Wolf, О. Л. Барбараш, Erhan Gökmen, Timothy E. O’Toole, Stephanie Lustgarten, Laurence Moore, Robert J. Motzer
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Robert J. Motzer, B. Yа. Alekseev, Sun Young Rha, Camillo Porta, Masatoshi Eto, Thomas Powles, Viktor Grünwald, Thomas E. Hutson, Evgeny Kopyltsov, María José Méndez-Vidal, Vadim Kozlov, Anna Alyasova, Sung‐Hoo Hong, Anil Kapoor, Teresa Alonso Gordoa, Jaime R. Merchan, Eric Winquist, Pablo Maroto, Jeffrey C. Goh, Miso Kim, Howard Gurney, Vijay Patel, Avivit Peer, Giuseppe Procopio, Toshio Takagi, Bohuslav Melichar, Frédéric Rolland, Ugo De Giorgi, Shirley Wong, Jens Bedke, Manuela Schmidinger, Corina E. Dutcus, Alan D. Smith, Lea Dutta, Kalgi Mody, Rodolfo F. Perini, Dongyuan Xing, Toni K. Choueiri
Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study
Toni K. Choueiri, Masatoshi Eto, Robert J. Motzer, Ugo De Giorgi, Tomáš Büchler, Naveen S. Basappa, María José Méndez-Vidal, Sergei Tjulandin, Se Hoon Park, Bohuslav Melichar, Thomas E. Hutson, C. Alemany, Bradley A. McGregor, Thomas Powles, Viktor Grünwald, B. Yа. Alekseev, Sun Young Rha, Evgeny Kopyltsov, Anil Kapoor, Teresa Alonso Gordoa, Jeffrey C. Goh, Michael Staehler, Jaime R. Merchan, Ran Xie, Rodolfo F. Perini, Kalgi Mody, Jodi A. McKenzie, Camillo Porta